Completed PHASE3 INTERVENTIONAL 2-arm NCT01529840

Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome

Norditropin Treatment in Subjects With Noonan Syndrome. Effects on Linear Growth and Final Height - Data Collection and Follow-up Visit

Sponsor: Novo Nordisk A/S

Conditions Genetic Disorder Noonan Syndrome

Interventions somatropin

Updated 7 times since 2017 Last updated: Jan 17, 2017 Started: Jun 30, 1990 Primary completion: Sep 30, 2005 Completion: Sep 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01529840, this PHASE3 trial focuses on Genetic Disorder and Noonan Syndrome and remains completed. Sponsored by Novo Nordisk A/S, it has been updated 7 times since 1990, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 1990

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gothenburg, Sweden